BioCryst pipeline update: five programs to enter clinic by 2025, R&D spend guided $230-240M in 2024

BIOCRYST PHARMACEUTICALS INC

BCX17725 (fusion protein KLK5 inhibitor) for Netherton syndrome entering clinic 2H 2024.
Avoralstat + Clearside SCS Microinjector for DME to enter clinic in 2025.
Oral C5 inhibitor for generalized myasthenia gravis to enter clinic in 2025.
Bifunctional complement inhibitor targeting multiple pathways for IgAN and lupus nephritis to enter clinic in 2025.
2024 R&D spending guided at $230-240M, up from projected 2023 spending of $25-35M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.